Drugs & AgingPub Date : 2026-11-07DOI: 10.1007/s40266-026-01345-2
Annabel J Chapman, Lisa M McCarthy, Nima Alaeiilkhchi, Aili V Langford, Shin J Liau, Darshna Goordeen, Emily Reeve, Wade Thompson
{"title":"Healthcare Professionals' Priorities for Guidelines on Deprescribing Antihyperglycemics: A Mixed-Methods Study.","authors":"Annabel J Chapman, Lisa M McCarthy, Nima Alaeiilkhchi, Aili V Langford, Shin J Liau, Darshna Goordeen, Emily Reeve, Wade Thompson","doi":"10.1007/s40266-026-01345-2","DOIUrl":"https://doi.org/10.1007/s40266-026-01345-2","url":null,"abstract":"<p><strong>Background: </strong>For older adults living with frailty and type 2 diabetes, reassessing the appropriateness of medications is important. This may include consideration of deprescribing (reducing or stopping) antihyperglycemic medications. Our deprescribing.org team created a guideline for deprescribing antihyperglycemics in 2017. To inform a guideline update, we conducted a prioritization exercise to ensure our update addresses current healthcare professional (HCP) needs and priorities.</p><p><strong>Objective: </strong>The aim was to establish HCP priorities with regards to the guideline topics, outcomes, and knowledge translation materials included with the 2017 guideline and identify gaps in the content to be added to the update.</p><p><strong>Methods: </strong>We conducted a sequential explanatory mixed-methods study between April and June 2025, including a survey open to participants globally, followed by focus groups open to participants in Canada. Quantitative survey data were analyzed using descriptive statistics. Qualitative data within the survey and focus group discussions were analyzed using summative content analysis and conventional content analysis, respectively.</p><p><strong>Results: </strong>All guideline topics proposed in the survey were considered either \"extremely important\" or \"important\" by the majority of participants. The outcome considered most critical for decision-making when deprescribing was clinical symptoms of hypoglycemia (91%). As a knowledge translation tool, a decision-support algorithm was considered important or extremely important by 84% of respondents. Qualitative findings highlighted considerations for incorporating novel antihyperglycemic agents into deprescribing decisions, cost implications for the patient, and knowledge translation resources (e.g., reporting templates) to support clear communication between prescribers, and patient education materials.</p><p><strong>Conclusions: </strong>The topics and outcomes included in deprescribing.org's 2017 antihyperglycemic deprescribing guideline were all considered important or extremely important by HCPs and therefore we will recommend that these be carried forward into the new guideline. Next steps will include reporting HCP priorities to the guideline panel and updating the systematic review for the guideline.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drugs & AgingPub Date : 2026-11-01Epub Date: 2026-10-26DOI: 10.1007/s40266-026-01343-4
Marcus Vetter
{"title":"Barriers and Opportunities for Implementing Precision Oncology in Geriatric Cancer Care.","authors":"Marcus Vetter","doi":"10.1007/s40266-026-01343-4","DOIUrl":"10.1007/s40266-026-01343-4","url":null,"abstract":"<p><p>Precision oncology can guide treatment selection and treatment omission in older adults, but molecular actionability alone does not establish an acceptable individual benefit-burden balance. This focused narrative review examines tumor biology, host vulnerability, and implementation barriers, prioritizing randomized trials, prospective cohorts, and guidance published during 2019-2025. Clonal hematopoiesis complicates plasma variant interpretation, and genomic risk must be distinguished from prediction of treatment benefit. The GAP70+ and GAIN trials demonstrate that geriatric assessment linked to management reduces serious treatment toxicity in general oncology; their results do not directly validate geriatric integration into molecular tumor boards. Older-adult studies including RESPECT, EORTC 75111-10114, Alliance A171601, and ASTER 70s inform specific biomarker-selected treatment decisions while exposing limitations in evidence for frail patients. Targeted treatment may complement chemotherapy as maintenance, and de-escalation requires indication-specific evidence. Genomic assays in early breast cancer should be requested when the result can change a realistic treatment choice, rather than offered or withheld solely according to age. Existing American Society of Clinical Oncology (ASCO), Food and Drug Administration (FDA), and European Organisation for Research and Treatment of Cancer (EORTC) responses to underrepresentation provide a foundation for more inclusive research. A proposed clinical framework combines validated molecular evidence, geriatric assessment, medication review, and shared decisions, with reassessment of function and goals. Prospective evaluation should establish whether this integration improves treatment delivery, function, quality of life, and goal concordance.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"991-999"},"PeriodicalIF":4.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13740112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149264396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Risk of Dementia With Renin-Angiotensin System Inhibitors Versus Calcium Channel Blockers in Hypertensive Adults: A Nationwide Multicenter Study.","authors":"Yinfang Sun, Zhixin Guo, Jinming Zhang, Mingzhen Pang, Ruixuan Chen, Caoxiang She, Shiyu Zhou, Hao Wang, Xian Shao, Sheng Nie","doi":"10.1007/s40266-026-01337-2","DOIUrl":"10.1007/s40266-026-01337-2","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to evaluate whether renin-angiotensin system inhibitors (RASIs) reduce dementia risk independently of blood pressure control compared with calcium channel blockers (CCBs) in antihypertensive-naïve adults with hypertension.</p><p><strong>Methods: </strong>This multicenter, new-user active comparator study included antihypertensive-naïve adults initiating RASIs or CCBs across 28 hospitals. Participants were matched 1:1 on baseline characteristics using propensity score matching (PSM). The primary outcome was incident all-cause dementia; secondary outcomes were Alzheimer's disease and vascular dementia. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression.</p><p><strong>Results: </strong>Of 164,918 eligible patients (median age 65 years [interquartile range 55-74]; 51.2% male), 54,042 PSM pairs initiating RASIs versus CCBs were included. During a median follow-up of 516 days, 344 incident dementia cases occurred. The incidence rate of all-cause dementia was lower among RASI initiators than CCB initiators (1.26 vs 1.89 per 1000 person-years). Initiation of RASIs was associated with a significantly lower risk of all-cause dementia (HR 0.68, 95% CI 0.55-0.84) and Alzheimer's disease (HR 0.59, 95% CI 0.43-0.81), but not vascular dementia (HR 0.74, 95% CI 0.50-1.11), compared with CCBs. There was no significant difference in dementia risk between initiators of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs).</p><p><strong>Conclusions: </strong>In adults with hypertension, initiation of RASIs was associated with a significantly lower risk of dementia compared with CCBs. No significant difference was observed between ACEIs and ARBs. Further validation is warranted.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"1001-1010"},"PeriodicalIF":4.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drugs & AgingPub Date : 2026-11-01Epub Date: 2026-09-30DOI: 10.1007/s40266-026-01338-1
Martin Wawruch, Mariana Mrazova, Viktor Foltin, Peter Kisac, Zuzana Mojzesova, Simona Gasparovicova, Jan Murin, Tomas Tesar, Miriam Vulevova, Petra Matalova, Sofa D Alfian, Emma Aarnio
{"title":"Patterns of Evidence-Based Medication Use in Older Adults with Chronic Heart Failure in Slovakia: A Population-Based Study Using the National Health Information Center Database.","authors":"Martin Wawruch, Mariana Mrazova, Viktor Foltin, Peter Kisac, Zuzana Mojzesova, Simona Gasparovicova, Jan Murin, Tomas Tesar, Miriam Vulevova, Petra Matalova, Sofa D Alfian, Emma Aarnio","doi":"10.1007/s40266-026-01338-1","DOIUrl":"10.1007/s40266-026-01338-1","url":null,"abstract":"<p><strong>Background: </strong>Prescribing of evidence-based heart failure (HF) medications in older adults varies across settings, and population-level data from Central and Eastern Europe are scarce. Our study aimed to (a) evaluate the use of evidence-based medications among older adults with chronic HF and (b) identify patient- and healthcare-related characteristics associated with the use of evidence-based medications.</p><p><strong>Methods: </strong>In our retrospective register-based study, all patients aged ≥ 65 years in whom at least one medication was prescribed in association with newly diagnosed HF during the period of 1 January 2016 to 31 December 2021 were included. Patients were divided into non-users, new users and prevalent users of evidence-based medications. Non-users were defined as patients who did not receive the specific medication class being analysed. New users were the patients in whom the use of such medications was initiated in association with the newly diagnosed HF without having a prescription for them during the previous 3 years. In prevalent users, these medications were used for diagnoses other than HF before inclusion in our study. Patient- and healthcare-related characteristics potentially associated with the use of evidence-based medications were evaluated with binary logistic regression models comparing the group of new users with non-users.</p><p><strong>Results: </strong>The following proportions of users (both new and prevalent) were observed in our study group of 111,774 patients: angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers/angiotensin receptor-neprilysin inhibitor were prescribed in 78.5% (95% confidence interval [CI] 78.3-78.8), β-blockers in 76.2% (95% CI 75.9-76.4), mineralocorticoid receptor antagonists in 41.1% (95% CI 40.8-41.4), digoxin in 13.5% (95% CI 13.3-13.7), ivabradine in 3.8% (95% CI 3.7-3.9) and sodium-glucose cotransporter-2 (SGLT2) inhibitors in 3.7% (95% CI 3.6-3.8) of patients. Specialisation of the physicians in internal medicine/cardiology, or in diabetology in the case of SGLT2 inhibitors, showed the strongest association with the prescription of analysed medications. Comorbidities were associated with the use of evaluated medications when they constituted indications or contraindications for their administration.</p><p><strong>Conclusion: </strong>Among older adults with HF, the prescription of evidence-based medications was strongly associated with physician specialty, reflecting the importance of specialised expertise in the management of HF.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"1037-1048"},"PeriodicalIF":4.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drugs & AgingPub Date : 2026-11-01Epub Date: 2026-09-28DOI: 10.1007/s40266-026-01333-6
Jessica McCann, Jen K Jennnings, Andy Husband, Darren M Ashcroft, Richard S Bourne
{"title":"Medication Appropriateness and Potentially Inappropriate Medications in Older Critical Care Patients: A Scoping Review.","authors":"Jessica McCann, Jen K Jennnings, Andy Husband, Darren M Ashcroft, Richard S Bourne","doi":"10.1007/s40266-026-01333-6","DOIUrl":"10.1007/s40266-026-01333-6","url":null,"abstract":"<p><strong>Background: </strong>Demand for care of older people in critical care units is increasing. During critical care, new medications are initiated. Assessment of potentially inappropriate medication is not routine within this setting, and the clinical utility of medication appropriateness tools, related interventions and their impact on outcomes in the older critical care population has not yet been reviewed.</p><p><strong>Objectives: </strong>To understand the extent and type of evidence in the assessment of medication appropriateness, intervention strategies and relationship between potentially inappropriate medication use and clinical outcomes in older people in critical care.</p><p><strong>Methods: </strong>The Preferred Reporting of Items for Systematic Reviews and Meta-Analyses extension for scoping reviews was followed. Embase, MEDLINE, CINAHL, APA PsycINFO and Web of Science were systematically searched (April 2025) for studies assessing medication use in critically ill older people (≥ 60 years). Eligible study designs included randomised and non-randomised trials, cohort studies, cross-sectional studies and case-control studies.</p><p><strong>Results: </strong>Ten studies (nine patient cohorts) were included. Most were cohort studies originating from North and South America. Benzodiazepines, opioids and antithrombotics were the most common potentially inappropriate medications reported, identified mostly by Beers Criteria and STOPP Criteria. Critical care length of stay was the most frequently associated clinical outcome. No intervention studies were identified.</p><p><strong>Conclusions: </strong>Medication appropriateness assessment tools have been used to a limited degree to assess medications in older critical care people. Further research is needed to establish their validity, clinical utility and impact on prescribing decisions and to evaluate interventions aimed at improving medication appropriateness and outcomes for older people in critical care.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"977-989"},"PeriodicalIF":4.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13739987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction: Cardiovascular-Related Polypharmacy and Its Association with Liver and Kidney Function: A Cross-Sectional Study Using Primary Care Data.","authors":"Caroline Trin, Harvey Jia Wei Koh, Zhomart Orman, Dianna J Magliano, Ella Zomer, Zanfina Ademi, Stella Talic","doi":"10.1007/s40266-026-01330-9","DOIUrl":"10.1007/s40266-026-01330-9","url":null,"abstract":"","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"1049-1054"},"PeriodicalIF":4.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13739946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drugs & AgingPub Date : 2026-11-01Epub Date: 2026-10-07DOI: 10.1007/s40266-026-01340-7
Miliça Paut Kusturica, M Teresa Peñarrubia-María, Lucy Anne Parker, Sara Mucherino, Enrica Menditto, Valentina Orlando, Ignacio Aznar Lou
{"title":"Benzodiazepine Prescription and Use in the Older Adults in Catalonia, Spain from 2018 to 2022: A Drug Utilization Study.","authors":"Miliça Paut Kusturica, M Teresa Peñarrubia-María, Lucy Anne Parker, Sara Mucherino, Enrica Menditto, Valentina Orlando, Ignacio Aznar Lou","doi":"10.1007/s40266-026-01340-7","DOIUrl":"10.1007/s40266-026-01340-7","url":null,"abstract":"<p><strong>Background and objective: </strong>Benzodiazepines (BZDs) remain among the most frequently prescribed psychotropic drugs in older adults, despite well-documented risks and guideline recommendations for short-term use. This study analyzed BZD prescribing trends among individuals aged ≥ 65 years in Catalonia, Spain, between 2018 and 2022.</p><p><strong>Methods: </strong>A retrospective drug utilization study was conducted using anonymized electronic health records from the SIDIAP (Information System for Research in Primary Care) database, covering approximately 80% of the Catalan population. All patients aged ≥ 65 years with at least one BZD prescription were included. Data were analyzed by sex, age group, onset of action, and duration of effect. Utilization was expressed in defined daily doses per 1000 inhabitants per day.</p><p><strong>Results: </strong>The study included 463,446 older adults (68.2% women; mean age 77.1 ± 8.0 years) with 1,731,408 BZD prescriptions. Rapid-onset BZDs accounted for 51.9% and intermediate-onset for 45.2% of prescriptions; slow-onset drugs were 2.95%. Intermediate-acting BZDs predominated by duration (47.6%), followed by short-acting BZDs (31.9%) and long-acting BZDs (20.4%). Women had higher use than men across all age groups (e.g., short-acting < 75 years: 233.6 vs 106.6 defined daily doses per 1000 inhabitants per day). Median treatment duration was longest for intermediate-acting BZDs (219 days, interquartile range 59-365) and intermediate-onset BZDs (221 days, interquartile range 59-365).</p><p><strong>Conclusions: </strong>Benzodiazepine prescribing among Catalan older adults remains high, dominated by rapid-onset and short-acting to intermediate-acting agents, with widespread long-term use. These findings highlight the need for structured medication reviews, deprescribing programs, and prescriber education to reduce inappropriate BZD exposure in this population.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"1011-1020"},"PeriodicalIF":4.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13740098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149126769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drugs & AgingPub Date : 2026-11-01Epub Date: 2026-10-16DOI: 10.1007/s40266-026-01342-5
Guangxiang Jiang, Guang Yang, Yixing Liu, Dongran Han
{"title":"Planned Antihypertensive Deprescribing in Long-Term Care Residents: A Systematic Review of Randomized Evidence.","authors":"Guangxiang Jiang, Guang Yang, Yixing Liu, Dongran Han","doi":"10.1007/s40266-026-01342-5","DOIUrl":"10.1007/s40266-026-01342-5","url":null,"abstract":"<p><strong>Background: </strong>Evidence supporting antihypertensive treatment in older adults is derived largely from populations that differ from long-term care residents, in whom frailty, dementia, multimorbidity, polypharmacy, and competing clinical priorities may alter the balance between preventive benefit and treatment burden.</p><p><strong>Objectives: </strong>The aim was to synthesize randomized evidence on planned antihypertensive deprescribing in institutional long-term care and determine whether clinically and methodologically comparable effects support a common treatment-effect estimate.</p><p><strong>Methods: </strong>Randomized or cluster-randomized studies of planned antihypertensive deprescribing in long-term care were systematically reviewed. MEDLINE/PubMed, Embase, CENTRAL, CINAHL Complete, Web of Science Core Collection, trial registries, and PROSPERO were searched from inception and updated to 20 August 2026. Meta-analysis was reserved for outcomes with at least two clinically and methodologically compatible estimates of a common, interpretable effect; otherwise, structured study-level synthesis was used. Result-specific risk of bias was assessed with the revised Cochrane risk-of-bias tool (RoB 2), and certainty with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tool.</p><p><strong>Results: </strong>Three randomized long-term care studies involving 1548 residents were included. Their populations, deprescribing strategies, monitoring, restart criteria, and follow-up differed substantially, and no outcome was considered sufficiently clinically and methodologically comparable for meta-analysis. RETREAT-FRAIL reported an adjusted hazard ratio (HR) for all-cause mortality of 1.02 (95% confidence interval 0.86-1.21) over a median potential follow-up of 38.4 months, whereas DANTON reported an HR of 1.65 (0.95-2.85) to 32 weeks; Gulla/COSMOS had no cluster-adjusted comparative mortality estimate. At 16 weeks in DANTON, deprescribing increased systolic blood pressure by 11.0 mmHg (5.6-16.4), increased diastolic blood pressure by 4.6 mmHg (1.1-8.1), and reduced the number of antihypertensive drugs by 1.2 (1.0-1.4). Evidence for hospitalization, falls, cardiovascular events, cognition, function, and quality of life remained sparse, outcome-specific, or at risk of bias.</p><p><strong>Conclusions: </strong>Randomized evidence for antihypertensive deprescribing in long-term care remains sparse and clinically heterogeneous. Within individual trials, supervised deprescribing reduced antihypertensive exposure and raised blood pressure, but the magnitude and clinical consequences varied by strategy and follow-up. Current evidence does not establish a common effect on mortality, hospitalization, or other resident-important outcomes, making trial-specific estimates and deprescribing protocols more informative than a single pooled treatment effect.</p><p><strong>Prospero registration: </strong>CRD420261370802.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"961-975"},"PeriodicalIF":4.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drugs & AgingPub Date : 2026-11-01Epub Date: 2026-09-15DOI: 10.1007/s40266-026-01336-3
Valentina M Srikartika, David Youens, Rachael Moorin, Ninh Ha
{"title":"Differences in Anticholinergic Exposure Assessment Across Burden Scales and Exposure Measures in a Population-Based Study: Implications for Targeted Deprescribing in Older Adults.","authors":"Valentina M Srikartika, David Youens, Rachael Moorin, Ninh Ha","doi":"10.1007/s40266-026-01336-3","DOIUrl":"10.1007/s40266-026-01336-3","url":null,"abstract":"<p><strong>Background: </strong>Anticholinergic burden scales and exposure measures can support medication review in older adults; however, different instruments may classify different groups of individuals as exposed. Population-level comparisons of burden scales and exposure measures that are feasible for administrative dispensing data remain limited.</p><p><strong>Objective: </strong>To compare six anticholinergic burden scales and exposure measures feasible for application to administrative dispensing data with respect to exposure classification, agreement, medication profiles and subgroup exposure patterns in older adults.</p><p><strong>Methods: </strong>This retrospective cross-sectional study was conducted in Western Australian residents aged ≥ 65 years during 2017-2018 using linked population-level administrative data. Anticholinergic exposure was calculated using three dose-based exposure measures, with standardised dose metrics and narrower medication lists and three broad-inclusion burden scales, with wider medication lists and graded potency ratings. Outcomes were classified as exposed (score > 0 within each scale or measure) and high exposure (scale- or measure-specific thresholds). Agreement was assessed using Cohen's kappa, medication profiles were described and adjusted subgroup patterns were compared using logistic regression.</p><p><strong>Results: </strong>Amongst 330,684 older adults, the proportion classified as exposed ranged from 13.1 to 53.6%, whilst the proportion classified as having high exposure ranged from 0.7 to 6.9%. Agreement in identifying exposed individuals was highest amongst dose-based exposure measures and lower between dose-based exposure measures and broad-inclusion burden scales. High-exposure overlap was limited, particularly for the modified Drug Burden Index. Dose-based exposure measures captured narrower medication profiles, dominated by tricyclic antidepressants, antipsychotics and urological antimuscarinics. Broad-inclusion burden scales captured a wider range of therapeutic classes, including medications with mild and moderate anticholinergic effects. Higher comorbidity was associated with greater exposure across all scales and measures, with the largest differences in the proportion classified as exposed observed for broad-inclusion burden scales.</p><p><strong>Conclusions: </strong>Scale or measure selection substantially influences who is classified as exposed, medication profiles and exposure patterns across subgroups. Anticholinergic burden scales and exposure measures are therefore not interchangeable and selection should reflect whether the intended purpose is population surveillance, comprehensive medication review or targeted deprescribing.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"1021-1035"},"PeriodicalIF":4.2,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13739931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148975691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Drugs & AgingPub Date : 2026-10-30DOI: 10.1007/s40266-026-01341-6
Margaretha T Dijk, Jacqueline G Hugtenburg, Eva van Galen, Rob J van Marum, Martin Smalbrugge, Eefje M Sizoo
{"title":"Views on Medication Changes Among Nursing Home Residents with a Limited Life Expectancy and Their Relatives: A Qualitative Study.","authors":"Margaretha T Dijk, Jacqueline G Hugtenburg, Eva van Galen, Rob J van Marum, Martin Smalbrugge, Eefje M Sizoo","doi":"10.1007/s40266-026-01341-6","DOIUrl":"https://doi.org/10.1007/s40266-026-01341-6","url":null,"abstract":"<p><strong>Background: </strong>Appropriate medication management for nursing home residents with a limited life expectancy may require deprescribing inappropriate medications and prescribing appropriate medications that were previously omitted. Knowledge on views of nursing home residents with a limited life expectancy and their relatives on medication changes, and their preferred involvement in decision-making is limited.</p><p><strong>Objective: </strong>To explore (1) views among nursing home residents with a limited life expectancy and their relatives on medication changes, and (2) how they want to be involved in the decision-making process.</p><p><strong>Methods: </strong>Twenty-three semi-structured interviews were conducted with nursing home residents with a limited life expectancy residing in psychogeriatric and somatic Dutch long-term care units and their relatives. Twelve residents and eleven relatives were included. The interviews were conducted individually and analysed thematically.</p><p><strong>Results: </strong>Nursing home residents and their relatives are generally open to medication changes; however, they are often unaware of this possibility. Their views on medication changes are shaped by the resident's current well-being and the perceived necessity of medication.They generally trust the physician and rely on the physician's initiative and advice. The degree of medication knowledge and preferences regarding decision-making involvement vary widely and depend on several factors.</p><p><strong>Conclusion: </strong>Because residents and relatives rely on the physician's initiative, physicians play a pivotal role in empowering them to participate in medication decisions. Proactively inquiring about their medication knowledge and preferences regarding medication use and decision-making may improve appropriate prescribing and shared decision-making.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149295622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}